Michael Spielman v. Genzyme Corp. And Genzyme Development Corp.

251 F.3d 1, 2001 U.S. App. LEXIS 10647, 2001 WL 538958
CourtCourt of Appeals for the First Circuit
DecidedMay 24, 2001
Docket00-1775
StatusPublished
Cited by180 cases

This text of 251 F.3d 1 (Michael Spielman v. Genzyme Corp. And Genzyme Development Corp.) is published on Counsel Stack Legal Research, covering Court of Appeals for the First Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Michael Spielman v. Genzyme Corp. And Genzyme Development Corp., 251 F.3d 1, 2001 U.S. App. LEXIS 10647, 2001 WL 538958 (1st Cir. 2001).

Opinion

LIPEZ, Circuit Judge.

Michael Spielman, the named plaintiff in a putative class action, appeals the district court’s dismissal of his suit for lack of subject matter jurisdiction. The court found that the plaintiffs individual damages claim failed to satisfy the amount-in-controversy minimum set by 28 U.S.C. § 1332 for entry into federal court. The court also rejected the plaintiffs alternative argument that his claim for attorney’s fees under Chapter 93A of the Massachusetts Consumer Protection Statute fulfilled the amount-in-controversy requirement because Massachusetts law allowed him to aggregate all of the fees anticipated by the class. We agree that Spielman does not meet the amount-in-controversy minimum and affirm the district court’s dismissal of his suit.

I.

In 1987, Michael Spielman, a New York resident, bought a limited partnership interest in Genzyme Clinical Partners, L.P. (GCP), which sought to develop a treatment for Gaucher’s disease. At that time Genzyme Development Corporation (Gen-zyme Development), a subsidiary of Gen-zyme Corporation (Genzyme), was the general partner of GCP. As general partner, Genzyme Development was obligated by law and by the limited partnership agreement to issue annual federal and state tax schedules to the limited partners. No schedules were issued between 1987 and 1990. In 1990, the GCP limited partners approved the sale of the partnership’s assets to Genzyme in exchange for shares of common stock. As a result, GCP was liquidated.

This transaction had tax implications for Spielman and some of the other 190 GCP limited partners who lived outside of Massachusetts. Sometime after Genzyme bought GCP, the Massachusetts Department of Revenue determined that the sale and liquidation was a taxable event under state law. In 1993, the Department notified the former limited partners who had not filed 1990 Massachusetts tax returns that they owed state taxes on their share of the liquidation income. Spielman was *3 assessed a tax of $10,820, which he did not pay. In 1995, the Department penalized Spielman for delinquent payment by doubling the amount he owed to $21,640.

On November 9, 1995, Spielman filed a class action in federal court on behalf of himself and similarly situated former GCP limited partners against Genzyme Development and Genzyme. 1 The complaint included claims of negligent misrepresentation, common law fraud, breach of fiduciary duty, and breach of contract. It alleged that Genzyme Development’s failure to issue the required 1990 tax schedules for GCP caused Spielman and the other class members to incur Massachusetts tax liability. As a resident of New York suing a Massachusetts corporation, Spielman asserted diversity jurisdiction under 28 U.S.C. § 1332, but did not specify a damages amount. At the time the suit was filed, § 1332(a) required that the “matter in controversy” exceed $50,000 for federal court jurisdiction to attach. See Act of Oct. 19, 1996, Pub.L. No. 104-317, 110 Stat. 3850 (amending 28 U.S.C. § 1332(a) so as to raise jurisdictional amount from $50,000 to $75,000).

Five days after filing the class action complaint, Spielman filed an appeal with the Massachusetts Appellate Tax Board to determine the taxes and penalty he owed for the GCP liquidation. On October 24, 1996, Genzyme filed a motion to dismiss for lack of subject matter jurisdiction, alleging that Spielman’s damages fell below the required $50,000 minimum. In opposition to this motion, Spielman filed an affidavit on November 21, 1996 claiming $21,640 in “double taxes,” $16,211.47 in interest, $11,246.48 in penalties, and $1,305 in accountant fees. The itemized damages totaled $50,402.95. The affidavit asserted, however, that Spielman’s damages as of the date his complaint was filed were $61,673.77, though it did not explain the $11,270.82 discrepancy between that amount and the itemized total.

On December 12, 1996, the district court denied Genzyme’s motion to dismiss for lack of subject matter jurisdiction, but stayed Spielman’s action pending the state Tax Board’s ruling on the amount of his tax liability. The court said: “This action ... has been prematurely brought. After a review of the papers and pleadings, it is not possible at this time to determine plaintiffs damages, as damages can be reasonably calculated only upon completion of the state administrative proceedings.”

This stay remained in place for more than two years. Then at a February 8, 1999 status conference, Spielman told the court that the Tax Board had assessed his final tax liability at $10,820 — the taxes he owed for GCP’s liquidation, with no assessment of penalties or interest. Spielman also said that to achieve this result he had paid attorney’s fees of $7,000 and accountant’s fees of $1,305, for a total of $8,305. Spielman told the court he would consider whether the Tax Board’s ruling meant that he could no longer meet the amount-in-controversy minimum. The next day, the court lifted the stay on Spielman’s class action.

Five months later, on July 16, 1999, Spielman asked the court for leave to file an amended complaint. The amendment alleged no new facts, but added a claim under Chapter 93A of the Massachusetts Consumer Protection Act, which permits prevailing plaintiffs to recover attorney’s fees as part of their damages award. Gen- *4 zyme protested, arguing that Spielman's attempt to amend the complaint was untimely and a "transparent attempt to establish federal court jurisdiction where none exists." On September 22, 1999, the court granted Spielman's request to amend the complaint, saying that the court's December 1996 stay accounted for the delayed filing of the amendment.

On November 2, 1999, Genzyme renewed its motion to dismiss for lack of subject matter jurisdiction, claiming that the state Tax Board ruling established that Spielman had incurred at most $8,305 in damages. 2 In opposition to this motion, Spielman argued that his damages claim for attorney's fees under Chapter 93A should include the fees for the class, and that aggregating the fees to him would boost his claim over the $50,000 minimum. Spielman also urged the court to exercise supplemental jurisdiction over the other members of the class even if they individually failed to meet the amount-in-controversy requirement. 3

On May 5, 2000, the district court granted Genzyme's motion to dismiss for lack of subject matter jurisdiction under Federal Rule of Civil Procedure 12(b)(1). The court found that the Tax Board's ruling meant that the damages that Spielman alleged on the face of his original complaint failed to satisfy the jurisdictional minimum at the time that complaint was filed.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
251 F.3d 1, 2001 U.S. App. LEXIS 10647, 2001 WL 538958, Counsel Stack Legal Research, https://law.counselstack.com/opinion/michael-spielman-v-genzyme-corp-and-genzyme-development-corp-ca1-2001.